- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0002 - Volume
850 - Avg. Volume
0 - Market Cap (intraday)
84,673 - Beta (5Y Monthly) 25.64
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
www.tetrabiopharma.comRecent News: TBPMQ
View MorePerformance Overview: TBPMQ
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TBPMQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TBPMQ
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.52%
Return on Equity (ttm)
-315.85%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-39.02M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
483.2k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.52M